Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BYSI Stock Forecast 2026-2027
$1.71
Current Price
$70.31M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BYSI Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BYSI Price Momentum
+1.8%
1 Week Change
+10.3%
1 Month Change
+0.6%
1 Year Change
+4.9%
Year-to-Date Change
-50.3%
From 52W High of $3.44
+45.5%
From 52W Low of $1.18
📊 TOP ANALYST CALLS
Did BYSI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Beyondspring is one of their latest high-conviction picks.
Latest BYSI Stock Price Targets & Analyst Predictions
BYSI has shown a year-to-date change of 4.9% and a 1-year change of 0.6%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BYSI. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BYSI Analyst Ratings
2
Buy
0
Hold
0
Sell
BYSI Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.71
Latest BYSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BYSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2023 | Baird | Joel Beatty | Outperform | Maintains | $1.25 |
| Dec 2, 2021 | Jefferies | Hold | Downgrade | $N/A | |
| Dec 2, 2021 | B of A Securities | Underperform | Downgrade | $N/A | |
| Dec 1, 2021 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Sep 20, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 9, 2021 | Baird | Outperform | Initiates | $N/A | |
| Aug 4, 2021 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Apr 5, 2021 | HC Wainwright & Co. | Neutral | Downgrade | $N/A | |
| Jan 11, 2021 | B of A Securities | Buy | Initiates | $N/A | |
| Dec 29, 2020 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Jun 15, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 30, 2020 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 7, 2020 | Jefferies | Buy | Initiates | $N/A | |
| Jan 10, 2020 | Nomura | Buy | Initiates | $N/A | |
| Jan 10, 2020 | Nomura Instinet | Buy | Initiates | $N/A | |
| Dec 3, 2019 | William Blair | Outperform | Initiates | $N/A | |
| Jun 22, 2018 | Maxim Group | Buy | Maintains | $N/A | |
| Apr 4, 2017 | Rodman & Renshaw | Buy | Initiates | $N/A |
BeyondSpring Inc. (BYSI) Competitors
The following stocks are similar to Beyondspring based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BYSI
Beyondspring
mkt cap
69.08M
BeyondSpring Inc. (BYSI) Financial Data
BeyondSpring Inc. has a market capitalization of $70.31M with a P/E ratio of -84.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +4.2%.
Valuation Metrics
Market Cap
$70.31M
Enterprise Value
$66.83M
P/E Ratio
-84.0x
PEG Ratio
0.6x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.2%
Current Ratio
1.1x
Debt/Equity
0.0x
ROE
+4.2%
ROA
-19.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BeyondSpring Inc. (BYSI) Business Model
About BeyondSpring Inc.
What They Do
Develops innovative cancer therapies.
Business Model
BeyondSpring focuses on advancing novel therapeutics for oncology, generating revenue through the development and potential commercialization of its therapeutics, particularly Plinabulin, which targets chemotherapy-induced neutropenia and cancer pathways.
Additional Information
As a clinical-stage biopharmaceutical company, BeyondSpring is part of a vital industry pushing for breakthroughs in cancer treatment, attracting investor interest due to its promising pipeline and the potential to significantly impact patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
44
CEO
Dr. Lan Huang Ph.D.
Country
United States
IPO Year
2017
Website
beyondspringpharma.comBeyondSpring Inc. (BYSI) Latest News & Analysis
Latest News
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) presented updated efficacy and safety data for its Phase 2 study on pembrolizumab, Plinabulin, and docetaxel in treating metastatic NSCLC at the 2026 ASCO Annual Meeting.
Why It Matters
The efficacy and safety data from BeyondSpring's cancer therapy study could impact stock performance, investor sentiment, and future funding opportunities, influencing overall market dynamics for biotech stocks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) will present Study 303 on patients with NSCLC at the ASCO Annual Meeting from May 29 to June 2, 2026, supported by Merck.
Why It Matters
The upcoming ASCO presentation on BeyondSpring's study may influence stock performance, as positive findings could attract investment and boost confidence in its cancer therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BeyondSpring Inc. reported Q1 2026 financial results, highlighting advancements in its cancer therapies, including Plinabulin's potential in ADC combinations and a new molecular glue degrader in clinical development.
Why It Matters
The advancements in BeyondSpring's cancer therapies and promising data on Plinabulin may enhance the company's market position and appeal to investors seeking growth in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Preclinical results presented at AACR 2026 indicate that Plinabulin significantly enhances complete response rates and survival when used with leading ADC drugs, with or without immunotherapy.
Why It Matters
Positive preclinical results for Plinabulin suggest potential for enhanced efficacy in cancer treatments, which may boost stock prices of involved biotech firms and attract investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BeyondSpring Files 2025 Annual Report on Form 10-K
2 months ago
Quick Summary
BeyondSpring Inc. filed its annual report on Form 10-K for FY 2025 with the SEC on March 25, 2026. The report includes audited financial statements and is available on their website.
Why It Matters
BeyondSpring's 10-K filing reveals its financial health and operational progress, influencing investor sentiment and stock valuation in the competitive biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BeyondSpring Inc. (NASDAQ: BYSI) will participate in the Immuno-Oncology 360° Conference from February 10-12, 2026, in Boston, showcasing its immune-modulating cancer therapies.
Why It Matters
Participation in the IO360° Conference highlights BeyondSpring's commitment to innovation and may attract investor interest in its immune-modulating cancer therapies, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BYSI Stock
What is BeyondSpring Inc.'s (BYSI) stock forecast for 2026?
Analyst forecasts for BeyondSpring Inc. (BYSI) are not currently available. The stock is trading at $1.71.
Is BYSI stock a good investment in 2026?
According to current analyst ratings, BYSI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BYSI stock?
Price predictions from Wall Street analysts for BYSI are not currently available. The stock is trading at $1.71.
What is BeyondSpring Inc.'s business model?
BeyondSpring focuses on advancing novel therapeutics for oncology, generating revenue through the development and potential commercialization of its therapeutics, particularly Plinabulin, which targets chemotherapy-induced neutropenia and cancer pathways.
What is the highest forecasted price for BYSI BeyondSpring Inc.?
Price targets from Wall Street analysts for BYSI are not currently available. The stock is trading at $1.71.
What is the lowest forecasted price for BYSI BeyondSpring Inc.?
Price targets from Wall Street analysts for BYSI are not currently available. The stock is trading at $1.71.
What is the overall BYSI consensus from analysts for BeyondSpring Inc.?
The overall analyst consensus for BYSI is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are BYSI stock price projections?
Stock price projections, including those for BeyondSpring Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 4:29 PM UTC